Feedback / Questions
OSM-0205 - Osmol Therap
https://www.businesswire.com/news/home/20230918920134/en/FDA-Notifies-Osmol-Therapeutics-that-the-First-in-Human-Phase-1-Clinical-Trial-of-OSM-0205-for-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy-CIPN-May-Proceed
Sep 18, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next